Clinical Psychopharmacology of Depression

抑郁症的临床精神药理学

基本信息

  • 批准号:
    MR/K022202/1
  • 负责人:
  • 金额:
    $ 228.35万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2013
  • 资助国家:
    英国
  • 起止时间:
    2013 至 无数据
  • 项目状态:
    已结题

项目摘要

Clinical depression is common and sometimes difficult to treat successfully. We need to develop better pharmacological treatments for depressed patients but this goal is hindered by a lack of knowledge of the brain chemistry involved in the illness. Two important chemical messengers, serotonin and glutamate, are thought to be involved in depression and in the present investigation we will use two advanced imaging techniques, positron emission tomography (PET) and magnetic resonance spectroscopy (MRS) to increase our knowledge of how these chemicals are involved in depression and its treatment. We will also link our findings to measures of inflammation because some depressed patents appear to have inflammatory changes in their blood and inflammation can affect serotonin and glutamate. It will greatly increase our understanding of the role of serotonin in depression if we could measure its release in the living human brain and in one project we will try to achieve this using PET imaging of a specific label of serotonin receptors in healthy volunteers whose brain serotonin levels have been temporarily lowered by a dietary manipulation. We will use MRS to investigate levels of brain glutamate. We will first study patients with hepatitis who are receiving the anti-viral agent, interferon, for the treatment of their viral disorder. Interferon is known to cause depression when it is used to treat hepatitis and we will make ratings of depression and look at changes in brain glutamate during interferon treatment. We will then use the same MRS examination to look at glutamate levels in patients with clinical depression. We will use a blood test called CRP to divide the patients up into those with significant inflammation and those without. We will then see whether the changes in glutamate in patients with inflammation resemble those seen in patients treated with interferon.The response of depressed patients to conventional antidepressant treatment with SSRIs is quite variable. We will therefore see whether the presence of inflammation affects the response to the SSRI drug, escitalopram. We predict that patients with high levels of CRP before treatment will do less well with antidepressant therapy. If this is the case CRP could become a useful clinical marker to decide who will do well with standard antidepressant treatment.
临床抑郁症很常见,有时很难成功治疗。我们需要为抑郁症患者开发更好的药物治疗方法,但由于缺乏对疾病所涉及的脑化学的了解,这一目标受到阻碍。两个重要的化学信使,血清素和谷氨酸,被认为是参与抑郁症,在本研究中,我们将使用两种先进的成像技术,正电子发射断层扫描(PET)和磁共振波谱(MRS),以增加我们的知识,这些化学物质是如何参与抑郁症及其治疗。我们还将把我们的发现与炎症的测量联系起来,因为一些抑郁症患者的血液中似乎有炎症变化,炎症会影响血清素和谷氨酸。如果我们能够测量5-羟色胺在活体人脑中的释放,这将极大地增加我们对5-羟色胺在抑郁症中的作用的理解。在一个项目中,我们将尝试通过对健康志愿者的5-羟色胺受体的特定标记进行PET成像来实现这一目标,这些志愿者的大脑5-羟色胺水平因饮食控制而暂时降低。我们将使用MRS来研究大脑谷氨酸水平。我们将首先研究正在接受抗病毒药物干扰素治疗病毒性疾病的肝炎患者。干扰素在治疗肝炎时会引起抑郁,我们将对抑郁进行评级,并观察干扰素治疗期间脑谷氨酸的变化。然后,我们将使用相同的MRS检查来观察临床抑郁症患者的谷氨酸水平。我们将使用一种称为CRP的血液测试将患者分为有明显炎症和没有炎症的患者。然后我们将观察炎症患者的谷氨酸变化是否与干扰素治疗患者相似。抑郁症患者对SSRIs常规抗抑郁治疗的反应差异很大。因此,我们将观察炎症的存在是否会影响对SSRI药物艾司西酞普兰的反应。我们预测,治疗前CRP水平高的患者抗抑郁治疗效果较差。如果是这样的话,CRP可能成为一个有用的临床标志物,以决定谁将与标准的抗抑郁药治疗。

项目成果

期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The effects of serotonin modulation on medial prefrontal connectivity strength and stability: A pharmacological fMRI study with citalopram.
Overnight transdermal scopolamine patch administration has no clear effect on cognition and emotional processing in healthy volunteers.
隔夜透皮东莨菪碱贴剂给药对健康志愿者的认知和情绪处理没有明显影响。
Acute neural effects of fluoxetine on emotional regulation in depressed adolescents.
  • DOI:
    10.1017/s0033291722001805
  • 发表时间:
    2023-07
  • 期刊:
  • 影响因子:
    6.9
  • 作者:
    Capitao, Liliana P.;Chapman, Robert;Filippini, Nicola;Wright, Lucy;Murphy, Susannah E.;James, Anthony;Cowen, Philip J.;Harmer, Catherine J.
  • 通讯作者:
    Harmer, Catherine J.
Treatment-resistant depression and peripheral C-reactive protein.
Treatment-resistant depression and peripheral C-reactive protein
难治性抑郁症和外周 C 反应蛋白
  • DOI:
    10.1101/197012
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Chamberlain S
  • 通讯作者:
    Chamberlain S
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Philip Cowen其他文献

136. Neural Response to Implicit Emotions as Biomarkers of Clinical Response to SSRI Treatment in Depression
  • DOI:
    10.1016/j.biopsych.2017.02.148
  • 发表时间:
    2017-05-15
  • 期刊:
  • 影响因子:
  • 作者:
    Beata Godlewska;Michael Browning;Ray Norbury;Artemis Igoumenou;Philip Cowen;Catherine Harmer
  • 通讯作者:
    Catherine Harmer
207. A Double-Blind Randomised Study Investigating Ketamine Sustained Effect on Stress Response
一项双盲随机研究:探究氯胺酮对应激反应的持续作用
  • DOI:
    10.1016/j.biopsych.2025.02.444
  • 发表时间:
    2025-05-01
  • 期刊:
  • 影响因子:
    9.000
  • 作者:
    Sara Costi;Pilar Artiach Hortelano;Erdem Pulcu;Rupert McShane;Philip Cowen;Catherine Harmer;Susannah Murphy
  • 通讯作者:
    Susannah Murphy
576. Histamine 3 Receptor Blockade Influences the Neural Dynamics of Multimodal Memory in Humans
576. 组胺3受体阻断影响人类多模态记忆的神经动力学
  • DOI:
    10.1016/j.biopsych.2025.02.815
  • 发表时间:
    2025-05-01
  • 期刊:
  • 影响因子:
    9.000
  • 作者:
    Michael Colwell;Fin Van Umm;Marieke Martens;Philip Cowen;Catherine Harmer;Susannah Murphy
  • 通讯作者:
    Susannah Murphy
5-HT4 Receptor Agonists Are a Promising New Approach for the Treatment of Depression
5 - 羟色胺4受体激动剂是一种治疗抑郁症的有前景的新方法
  • DOI:
    10.1016/j.biopsych.2025.02.091
  • 发表时间:
    2025-05-01
  • 期刊:
  • 影响因子:
    9.000
  • 作者:
    Susannah Murphy;Angharad de Cates;Catherine Harmer;Paul Harrison;Philip Cowen;Maxime Taquet
  • 通讯作者:
    Maxime Taquet
245. The Effects of Ebselen on Brain Neurochemistry in Depressed Patients on Antidepressants
  • DOI:
    10.1016/j.biopsych.2024.02.480
  • 发表时间:
    2024-05-15
  • 期刊:
  • 影响因子:
  • 作者:
    Fitri Fareez Ramli;Nisha Singh;Philip Cowen;Beata Godlewska
  • 通讯作者:
    Beata Godlewska

Philip Cowen的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Philip Cowen', 18)}}的其他基金

Clinical Psychopharmacology of Depression
抑郁症的临床精神药理学
  • 批准号:
    MR/S003037/1
  • 财政年份:
    2019
  • 资助金额:
    $ 228.35万
  • 项目类别:
    Research Grant
Use of biomarkers to detect pre-symptomatic medical co-morbidity in young people at familial risk of depression
使用生物标志物检测有抑郁症家族风险的年轻人的症状前医学共病
  • 批准号:
    G0900576/1
  • 财政年份:
    2010
  • 资助金额:
    $ 228.35万
  • 项目类别:
    Research Grant
Clinical Psychopharmacology of 5-HT
5-HT的临床精神药理学
  • 批准号:
    G0701421/1
  • 财政年份:
    2008
  • 资助金额:
    $ 228.35万
  • 项目类别:
    Research Grant
Impaired neural responses to the sight and taste of chocolate: A model of anhedonia in depression.
对巧克力视觉和味道的神经反应受损:抑郁症的快感缺失模型。
  • 批准号:
    G0800905/1
  • 财政年份:
    2008
  • 资助金额:
    $ 228.35万
  • 项目类别:
    Research Grant
Cortical GABA and emotional processing in young people at risk of depression
有抑郁风险的年轻人的皮质 GABA 和情绪处理
  • 批准号:
    G0600179/1
  • 财政年份:
    2006
  • 资助金额:
    $ 228.35万
  • 项目类别:
    Research Grant

相似海外基金

Unlocking the psychopharmacology of psychedelics
解锁迷幻药的精神药理学
  • 批准号:
    2626461
  • 财政年份:
    2021
  • 资助金额:
    $ 228.35万
  • 项目类别:
    Studentship
SSA: Unlocking the psychopharmacology of psychedelics
SSA:解锁迷幻药的精神药理学
  • 批准号:
    2599045
  • 财政年份:
    2021
  • 资助金额:
    $ 228.35万
  • 项目类别:
    Studentship
Preclinical Psychopharmacology of Substance Abuse
药物滥用的临床前精神药理学
  • 批准号:
    10553641
  • 财政年份:
    2020
  • 资助金额:
    $ 228.35万
  • 项目类别:
Preclinical Psychopharmacology of Substance Abuse
药物滥用的临床前精神药理学
  • 批准号:
    9891589
  • 财政年份:
    2020
  • 资助金额:
    $ 228.35万
  • 项目类别:
Preclinical Psychopharmacology of Substance Abuse
药物滥用的临床前精神药理学
  • 批准号:
    10436778
  • 财政年份:
    2020
  • 资助金额:
    $ 228.35万
  • 项目类别:
Clinical Psychopharmacology of Depression
抑郁症的临床精神药理学
  • 批准号:
    MR/S003037/1
  • 财政年份:
    2019
  • 资助金额:
    $ 228.35万
  • 项目类别:
    Research Grant
Research for development of multidisciplinary treatment to prevent chronic pain: Examination of combination of psychopharmacology in physical therapy
预防慢性疼痛的多学科治疗发展研究:精神药理学与物理治疗相结合的检验
  • 批准号:
    16K01525
  • 财政年份:
    2016
  • 资助金额:
    $ 228.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A flexible high throughput analytical system for psychopharmacology and drug discovery
用于精神药理学和药物发现的灵活高通量分析系统
  • 批准号:
    LE120100177
  • 财政年份:
    2012
  • 资助金额:
    $ 228.35万
  • 项目类别:
    Linkage Infrastructure, Equipment and Facilities
Psychopharmacology of plants and their metabolites used as marijuana substitutes
用作大麻替代品的植物及其代谢物的精神药理学
  • 批准号:
    8046170
  • 财政年份:
    2011
  • 资助金额:
    $ 228.35万
  • 项目类别:
Psychopharmacology of plants and their metabolites used as marijuana substitutes
用作大麻替代品的植物及其代谢物的精神药理学
  • 批准号:
    8279212
  • 财政年份:
    2011
  • 资助金额:
    $ 228.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了